Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

Enhertu is supplied in a single-dose vial containing 100mg of lyophilized powder for reconstitution and further dilution prior to IV infusion. Patients should be selected for treatment with ...

Enhertu (fam-trastuzumab deruxtecan-nxki) can cause side effects that range from mild to serious. More common side effects include hair loss, nausea, and vomiting. If Enhertu side effects become ...

Welcome, ladies and gentlemen, to AstraZeneca's full-year and Q4 2024 results conference call for investors and analysts. Before I hand over to AstraZeneca, I'd like to read the safe harbor statement.

If that does happen, HER2 inhibitor Enhertu could become the first drug ... a tall order for such a large molecule – rather than by intravenous infusion. That could make it possible for patients ...

Rosie Hawkins wanted to give son Jonathan, six, and daughter Freya, one, letters to remember her by right into old age ...

The FDA made strides in R/R T-cell lymphoma and breast cancer. An AI tool aids pathologists and other positive updates in gastric cancer and NSCLC.

A MUM-of-two diagnosed with terminal breast cancer after her second round of IVF has written cards for both of her children ...

Enhertu (trastuzumab deruxtecan), which is cleared for second-line use only and is delivered as an intravenous infusion. Enhertu was given accelerated approval for this indication by the FDA in 2022.

The DXd ADC portfolio currently consists of ENHERTU, a HER2 directed ADC ... open-label phase 3 trial evaluating the efficacy and safety of intravenous DATROWAY (6 mg/kg) once per 21-day cycle versus ...

The DXd ADC portfolio currently consists of ENHERTU, a HER2 directed ADC ... DATROWAY was administered by intravenous infusion once every three weeks. The median duration of treatment was 6.7 months ...

Full prescribing information for Enhertu will be posted on Drugs@FDA ... to receive either fam-trastuzumab deruxtecan-nxki 5.4 mg/kg (N=436) by intravenous infusion every three weeks or physician’s ...